Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripot...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported its financial results for the third quarter ended September 28, ...
Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced the successful completion of its Phase 1 single and multiple ascending dose (SAD/MAD) clinical ...
Singular Genomics Systems, a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and cli...
Ecolab closed on the sale of its global surgical solutions business to Medline for total consideration of approximately $950 million in cash. With Ecolab...
Vision is to establish a leading ADC developer to treat high unmet need diseases such as cancer. Founded by the team that founded and sold Emergence T...
Asensus Surgical, , a global leader of innovative digital solutions for the operating room, today announced that it has entered into a definitive merger ...
Johnson & Johnson announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to...
Immediately after the effective time of the Acquisition, and before giving effect to the concurrent private placement the former stockholders of Bi...
In a strategic shift that promises to redefine the pharmaceutical industry, Novo Holdings, the investment arm of Novo Nordisk's parent foundation, has unve...
In a move that adds an intriguing layer to the IPO dynamics, Alto has granted underwriters a 30-day option to scoop up an additional 1,206,000 shares of co...
“The closing of the Mirati transaction is a significant milestone in our efforts to further diversify our oncology portfolio and strengthen our pipel...
Pfizer does not endorse TRC Capital Investment’s unsolicited mini-tender offer and recommends that stockholders do not tender their shares in respons...
QIAGEN announced a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repurchase tha...
© 2024 Biopharma Boardroom. All Rights Reserved.
